• Philip B Adamson, William T Abraham, Robert C Bourge, Maria Rosa Costanzo, Ayesha Hasan, Chethan Yadav, John Henderson, Pam Cowart, and Lynne Warner Stevenson.
• From the Heart Failure Institute, Oklahoma Heart Hospital, Department of Physiology, University of Oklahoma Health Sciences Center, Oklahoma City (P.B.A.); Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University, Columbus (W.T.A., A.H.); Department of Medicine, University of Alabama at Birmingham (R.C.B.); Advocate Medical Group-Midwest Heart Specialists Heart Failure and Pulmonary Arterial Hypertension Programs, Edward Hospital Center for Advanced Heart Failure, Naperville, IL (M.R.C.); CardioMEMS, Inc, Atlanta, GA (C.Y., J.H., P.C.); and Advanced Heart Disease Section, Heart and Vascular Center, Brigham and Women's Hospital, Boston, MA (L.W.S.). padamson@okheart.com.
• Circ Heart Fail. 2014 Nov 1; 7 (6): 935-44.

BackgroundNo treatment strategies have been demonstrated to be beneficial for the population for patients with heart failure (HF) and preserved ejection fraction (EF).Methods And ResultsThe CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) trial was a prospective, single-blinded, randomized controlled clinical trial testing the hypothesis that hemodynamically guided HF management decreases decompensation leading to hospitalization. Of the 550 patients enrolled in the study, 119 had left ventricular EF ≥40% (average, 50.6%), 430 patients had low left ventricular EF (<40%; average, 23.3%), and 1 patient had no documented left ventricular EF. A microelectromechanical system pressure sensor was permanently implanted in all participants during right heart catheterization. After implant, subjects were randomly assigned in single-blind fashion to a treatment group in whom daily uploaded pressures were used in a treatment strategy for HF management or to a control group in whom standard HF management included weight-monitoring, and pressures were uploaded but not available for investigator use. The primary efficacy end point of HF hospitalization rate >6 months for preserved EF patients was 46% lower in the treatment group compared with control (incidence rate ratio, 0.54; 95% confidence interval, 0.38-0.70; P<0.0001). After an average of 17.6 months of blinded follow-up, the hospitalization rate was 50% lower (incidence rate ratio, 0.50; 95% confidence interval, 0.35-0.70; P<0.0001). In response to pulmonary artery pressure information, more changes in diuretic and vasodilator therapies were made in the treatment group.ConclusionsHemodynamically guided management of patients with HF with preserved EF reduced decompensation leading to hospitalization compared with standard HF management strategies.Clinical Trial Registration Urlhttp://www.clinicaltrials.gov. Unique identifier: NCT00531661.© 2014 American Heart Association, Inc.

23 keywords...

hide…